<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00315393</url>
  </required_header>
  <id_info>
    <org_study_id>VCRC5505</org_study_id>
    <secondary_id>U54AR057319</secondary_id>
    <nct_id>NCT00315393</nct_id>
  </id_info>
  <brief_title>Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis</brief_title>
  <official_title>Determining Disease Activity Biomarkers in Individuals With Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Office of Rare Diseases (ORD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rare Diseases Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA) are two&#xD;
      rare immune system disorders that cause the inflammation of blood vessels, or vasculitis. In&#xD;
      order to properly treat these diseases, it is critical that the level of disease activity can&#xD;
      be determined over the course of the disease. The purpose of this study is to determine new&#xD;
      biological markers, or biomarkers, that may be used to assess the severity of disease in&#xD;
      people with GPA or MPA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GPA and MPA are two autoimmune disorders that cause systemic vasculitis. GPA commonly affects&#xD;
      the upper respiratory tract, the lungs, and the kidneys. MPA is marked by kidney&#xD;
      inflammation, weight loss, skin lesions, nerve damage, and fever. Many patients with WG or&#xD;
      MPA show no visible symptoms of active disease; it is known that underlying subclinical&#xD;
      disease activity leads to long-term damage in these patients. Also, because it is difficult&#xD;
      to monitor WG and MPA disease activity, it is difficult for clinicians to know when and how&#xD;
      to treat these patients. This study will use new scientific methods to identify new&#xD;
      biomarkers that can be used to monitor disease activity in GPA and MPA patients. These&#xD;
      biomarkers may be used to help direct clinical care for GPA and MPA patients and assist in&#xD;
      future drug development.&#xD;
&#xD;
      Study visits will occur monthly for the first year, then every 3 months thereafter for the&#xD;
      remainder of the study. Blood and urine collection will occur at every visit. A physical exam&#xD;
      and medical and medication history will occur every 3 months; also, participants will be&#xD;
      asked to complete several questionnaires to assess disease activity, health status, and&#xD;
      tobacco, alcohol, and drug use. Participants may have additional study visits if a disease&#xD;
      flare or disease-related complications occur during the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Discover biomarkers in GPA/MPA capable of measuring disease activity and response to treatment.</measure>
    <time_frame>Study completion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure the predictive value of biomarkers for clinical outcome in GPA/MPA</measure>
    <time_frame>Study completion.</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Granulomatosis With Polyangiitis</condition>
  <condition>Microscopic Polyangiitis</condition>
  <condition>Wegener's</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood (serum and plasma), urine, and DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with granulomatosis with polyangiitis (Wegener's)and microscopic polyangiitis.&#xD;
        Enrollment will be sequential and participants will have disease in various stages and of&#xD;
        different duration.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of GPA or MPA. Widely accepted diagnostic criteria, as opposed to&#xD;
             classification criteria or definitions, have not been developed for GPA and MPA.&#xD;
&#xD;
          -  For diagnosis of GPA, meets at least 2 of the following 5 modified American College of&#xD;
             Rheumatology (ACR) criteria:&#xD;
&#xD;
               1. Nasal or oral inflammation with oral ulcers or nasal discharge with pus or blood&#xD;
&#xD;
               2. Abnormal chest radiograph with nodules, fixed infiltrates, or cavities&#xD;
&#xD;
               3. Urinary sediment with microhematuria or red cell casts&#xD;
&#xD;
               4. Granulomatous inflammation within the wall of an artery or in the perivascular&#xD;
                  area on biopsy&#xD;
&#xD;
               5. Antineutrophil cytoplasmic antibody (ANCA) positive by enzyme immunoassay for&#xD;
                  either PR3- or MPO-ANCA&#xD;
&#xD;
          -  For diagnosis of MPA, meets the Chapel Hill Consensus Conference Definition for MPA:&#xD;
&#xD;
               1. Necrotizing vasculitis, with few or no immune deposits, that affects small&#xD;
                  vessels (i.e., capillaries, venules, arterioles)&#xD;
&#xD;
               2. Necrotizing arteritis involving small- and medium-sized arteries may be present&#xD;
&#xD;
               3. Necrotizing glomerulonephritis is very common&#xD;
&#xD;
               4. Pulmonary capillaritis often occurs&#xD;
&#xD;
          -  Parent or guardian willing to provide informed consent, if applicable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Simultaneous diagnoses of both GPA and MPA&#xD;
&#xD;
          -  Granulomatosis with polyangiitis (Churg-Strauss)&#xD;
&#xD;
          -  Takayasu's arteritis&#xD;
&#xD;
          -  Giant cell arteritis&#xD;
&#xD;
          -  Polyarteritis nodosa&#xD;
&#xD;
          -  Cogan's syndrome&#xD;
&#xD;
          -  Behcet's disease&#xD;
&#xD;
          -  Sarcoidosis&#xD;
&#xD;
          -  Kawasaki disease&#xD;
&#xD;
          -  Tuberculosis or any atypical mycobacterial infections&#xD;
&#xD;
          -  Deep fungal infections&#xD;
&#xD;
          -  Lymphoma, lymphomatoid granulomatosis, or any other type of cancer that mimics&#xD;
             anti-neutrophil cytoplasmic antibody-associated vasculitis (AAVs)&#xD;
&#xD;
          -  Cryoglobulinemic vasculitis&#xD;
&#xD;
          -  Systemic lupus erythematosus&#xD;
&#xD;
          -  Rheumatoid arthritis&#xD;
&#xD;
          -  Mixed connective tissue disease or any overlapping autoimmune syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter A. Merkel, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rarediseasesnetwork.org/cms/vcrc/</url>
    <description>Vasculitis Clinical Research Consortium</description>
  </link>
  <link>
    <url>http://rarediseasesnetwork.org/</url>
    <description>Rare Diseases Clinical Research Consortium</description>
  </link>
  <reference>
    <citation>Borgmann S, Haubitz M. Genetic impact of pathogenesis and prognosis of ANCA-associated vasculitides. Clin Exp Rheumatol. 2004;22(6 Suppl 36):S79-86. Review.</citation>
    <PMID>15675141</PMID>
  </reference>
  <reference>
    <citation>Cooley P, Taylor KH, Czika W, Seifer C, Taylor JF. Analysis of a biomarker for Wegener's granulomatosis. Int J Immunogenet. 2005 Aug;32(4):237-43.</citation>
    <PMID>16026591</PMID>
  </reference>
  <reference>
    <citation>Jagiello P, Gross WL, Epplen JT. Complex genetics of Wegener granulomatosis. Autoimmun Rev. 2005 Jan;4(1):42-7. Review.</citation>
    <PMID>15652778</PMID>
  </reference>
  <reference>
    <citation>Radice A, Sinico RA. Antineutrophil cytoplasmic antibodies (ANCA). Autoimmunity. 2005 Feb;38(1):93-103. Review.</citation>
    <PMID>15804710</PMID>
  </reference>
  <reference>
    <citation>Stone JH, Rajapakse VN, Hoffman GS, Specks U, Merkel PA, Spiera RF, Davis JC, St Clair EW, McCune J, Ross S, Hitt BA, Veenstra TD, Conrads TP, Liotta LA, Petricoin EF 3rd; Wegener's Granulomatosis Etanercept Trial Research Group. A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis. Arthritis Rheum. 2005 Mar;52(3):902-10.</citation>
    <PMID>15751091</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 14, 2006</study_first_submitted>
  <study_first_submitted_qc>April 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2006</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Peter Merkel</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>GPA</keyword>
  <keyword>MPA</keyword>
  <keyword>WG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Microscopic Polyangiitis</mesh_term>
    <mesh_term>Systemic Vasculitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

